The history of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated significant returns, the expiration of its patent opened the floodgates to off-brand https://thebookmarkid.com/story21750980/the-copyright-and-the-pharmaceutical-industry-a-risky-investment